Clinical Trials Logo

Pancreatic Cancer Resectable clinical trials

View clinical trials related to Pancreatic Cancer Resectable.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05483257 Completed - Clinical trials for Pancreatic Cancer Resectable

Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Start date: March 14, 2018
Phase:
Study type: Observational

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

NCT ID: NCT04224402 Completed - Clinical trials for Pancreatic Cancer Resectable

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Start date: January 31, 2020
Phase: Phase 2
Study type: Interventional

This prospective and open-label study evaluates the efficacy and safety of mFOLFIRINOX as postoperative chemotherapy in treating Chinese patients with pancreatic cancer after R0/R1 resection.